Skip to main content
Erschienen in: Journal of Neuro-Oncology 1/2013

01.05.2013 | Clinical Study

Seizures during the management of high-grade gliomas: clinical relevance to disease progression

verfasst von: Young-Hoon Kim, Chul-Kee Park, Tae Min Kim, Seung Hong Choi, Yu Jung Kim, Byung Se Choi, Jung Ho Han, Se-Hoon Lee, Chae-Yong Kim, In Ah Kim, Dae Seog Heo, Il Han Kim, Dong Gyu Kim, Hee-Won Jung

Erschienen in: Journal of Neuro-Oncology | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

This study was performed to evaluate the incidence of seizures with its implications on disease progression and the diagnostic value of post-ictal magnetic resonance images (MRI) during the management of high-grade gliomas (HGGs). A total of 406 consecutive patients with newly diagnosed HGGs were retrospectively reviewed. The incidence of seizures during the management was investigated. In patients who experienced a seizure, the causality between seizures and disease progression was assessed by pre-ictal, post-ictal (<1 month), and follow-up (<3 months) MRI. After a median follow-up of 17.4 months (range 0.1–88.3), seizures developed in 127 patients (31 %). Of the 127 patients, radiological progression at the post-ictal MRI was found in 83 patients (65 %) and the follow-up MRI confirmed progression in 79 patients (62 %). Four other patients (3 %) were shown to be progression-free. Among those without radiological progression at the post-ictal MRI, the follow-up MRI confirmed progression-free in 31 patients (24 %); however, 13 patients (10 %) revealed eventual progression. In the patients with a seizure, absence of preoperative seizures (p = 0.003), <95 % tumor resection (p = 0.001), and pre-ictal Karnofsky Performance Scale score ≤70 (p = 0.025) were significantly associated with disease progression. During the management of HGG, 31 % of patients experienced seizures; of these patients, 72 % harbored progressive disease. The post-ictal MRI is useful for detecting disease progression; however, there are pitfalls. Clinical settings should be considered together for diagnosing disease progression in patients with seizures.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996. doi:10.1056/NEJMoa043330 PubMedCrossRef Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996. doi:10.​1056/​NEJMoa043330 PubMedCrossRef
3.
Zurück zum Zitat Kim YH, Park CK, Cho WH, Kim IA, Moon S, Choe G, Park SH, Kim IH, Kim DG, Jung HW, Lee MM, Bae SH, Cha SH, Kim CY (2011) Temozolomide during and after radiation therapy for WHO grade III gliomas: preliminary report of a prospective multicenter study. J Neurooncol 103(3):503–512. doi:10.1007/s11060-010-0404-5 PubMedCrossRef Kim YH, Park CK, Cho WH, Kim IA, Moon S, Choe G, Park SH, Kim IH, Kim DG, Jung HW, Lee MM, Bae SH, Cha SH, Kim CY (2011) Temozolomide during and after radiation therapy for WHO grade III gliomas: preliminary report of a prospective multicenter study. J Neurooncol 103(3):503–512. doi:10.​1007/​s11060-010-0404-5 PubMedCrossRef
4.
Zurück zum Zitat Chaichana KL, Parker SL, Olivi A, Quinones-Hinojosa A (2009) Long-term seizure outcomes in adult patients undergoing primary resection of malignant brain astrocytomas. Clinical article. J Neurosurg 111(2):282–292. doi:10.3171/2009.2.jns081132 PubMedCrossRef Chaichana KL, Parker SL, Olivi A, Quinones-Hinojosa A (2009) Long-term seizure outcomes in adult patients undergoing primary resection of malignant brain astrocytomas. Clinical article. J Neurosurg 111(2):282–292. doi:10.​3171/​2009.​2.​jns081132 PubMedCrossRef
5.
Zurück zum Zitat Pace A, Bove L, Innocenti P, Pietrangeli A, Carapella CM, Oppido P, Raus L, Occhipinti E, Jandolo B (1998) Epilepsy and gliomas: incidence and treatment in 119 patients. J Exp Clin Cancer Res 17(4):479–482PubMed Pace A, Bove L, Innocenti P, Pietrangeli A, Carapella CM, Oppido P, Raus L, Occhipinti E, Jandolo B (1998) Epilepsy and gliomas: incidence and treatment in 119 patients. J Exp Clin Cancer Res 17(4):479–482PubMed
6.
Zurück zum Zitat Hwang SL, Lin CL, Lee KS, Lieu AS, Kuo TH, Chang CZ, Yen CP, Loh JK, Huang TY, Howng SL (2004) Factors influencing seizures in adult patients with supratentorial astrocytic tumors. Acta Neurochir (Wien) 146(6):589–594. doi:10.1007/s00701-004-0266-8 CrossRef Hwang SL, Lin CL, Lee KS, Lieu AS, Kuo TH, Chang CZ, Yen CP, Loh JK, Huang TY, Howng SL (2004) Factors influencing seizures in adult patients with supratentorial astrocytic tumors. Acta Neurochir (Wien) 146(6):589–594. doi:10.​1007/​s00701-004-0266-8 CrossRef
7.
Zurück zum Zitat Hwang SL, Lieu AS, Kuo TH, Lin CL, Chang CZ, Huang TY, Howng SL (2001) Preoperative and postoperative seizures in patients with astrocytic tumours: analysis of incidence and influencing factors. J Clin Neurosci 8(5):426–429. doi:10.1054/jocn.2000.0825 PubMedCrossRef Hwang SL, Lieu AS, Kuo TH, Lin CL, Chang CZ, Huang TY, Howng SL (2001) Preoperative and postoperative seizures in patients with astrocytic tumours: analysis of incidence and influencing factors. J Clin Neurosci 8(5):426–429. doi:10.​1054/​jocn.​2000.​0825 PubMedCrossRef
8.
Zurück zum Zitat Telfeian AE, Philips MF, Crino PB, Judy KD (2001) Postoperative epilepsy in patients undergoing craniotomy for glioblastoma multiforme. J Exp Clin Cancer Res 20(1):5–10PubMed Telfeian AE, Philips MF, Crino PB, Judy KD (2001) Postoperative epilepsy in patients undergoing craniotomy for glioblastoma multiforme. J Exp Clin Cancer Res 20(1):5–10PubMed
9.
Zurück zum Zitat Boarini DJ, Beck DW, VanGilder JC (1985) Postoperative prophylactic anticonvulsant therapy in cerebral gliomas. Neurosurgery 16(3):290–292PubMedCrossRef Boarini DJ, Beck DW, VanGilder JC (1985) Postoperative prophylactic anticonvulsant therapy in cerebral gliomas. Neurosurgery 16(3):290–292PubMedCrossRef
10.
Zurück zum Zitat Moots PL, Maciunas RJ, Eisert DR, Parker RA, Laporte K, Abou-Khalil B (1995) The course of seizure disorders in patients with malignant gliomas. Arch Neurol 52(7):717–724PubMedCrossRef Moots PL, Maciunas RJ, Eisert DR, Parker RA, Laporte K, Abou-Khalil B (1995) The course of seizure disorders in patients with malignant gliomas. Arch Neurol 52(7):717–724PubMedCrossRef
11.
Zurück zum Zitat Tandon PN, Mahapatra AK, Khosla A (2001) Epileptic seizures in supratentorial gliomas. Neurol India 49(1):55–59PubMed Tandon PN, Mahapatra AK, Khosla A (2001) Epileptic seizures in supratentorial gliomas. Neurol India 49(1):55–59PubMed
14.
Zurück zum Zitat Rheims S, Ricard D, van den Bent M, Taillandier L, Bourg V, Desestret V, Cartalat-Carel S, Hermier M, Monjour A, Delattre JY, Sanson M, Honnorat J, Ducray F (2011) Peri-ictal pseudoprogression in patients with brain tumor. Neuro Oncol 13(7):775–782. doi:10.1093/neuonc/nor082 PubMedCrossRef Rheims S, Ricard D, van den Bent M, Taillandier L, Bourg V, Desestret V, Cartalat-Carel S, Hermier M, Monjour A, Delattre JY, Sanson M, Honnorat J, Ducray F (2011) Peri-ictal pseudoprogression in patients with brain tumor. Neuro Oncol 13(7):775–782. doi:10.​1093/​neuonc/​nor082 PubMedCrossRef
15.
Zurück zum Zitat Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8(7):1277–1280PubMed Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8(7):1277–1280PubMed
16.
Zurück zum Zitat Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G, Bertorelle R, Bartolini S, Calbucci F, Andreoli A, Frezza G, Leonardi M, Spagnolli F, Ermani M (2008) MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26(13):2192–2197. doi:10.1200/JCO.2007.14.8163 PubMedCrossRef Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G, Bertorelle R, Bartolini S, Calbucci F, Andreoli A, Frezza G, Leonardi M, Spagnolli F, Ermani M (2008) MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26(13):2192–2197. doi:10.​1200/​JCO.​2007.​14.​8163 PubMedCrossRef
18.
Zurück zum Zitat Lee JW, Wen PY, Hurwitz S, Black P, Kesari S, Drappatz J, Golby AJ, Wells WM 3rd, Warfield SK, Kikinis R, Bromfield EB (2010) Morphological characteristics of brain tumors causing seizures. Arch Neurol 67(3):336–342. doi:10.1001/archneurol.2010.2 PubMedCrossRef Lee JW, Wen PY, Hurwitz S, Black P, Kesari S, Drappatz J, Golby AJ, Wells WM 3rd, Warfield SK, Kikinis R, Bromfield EB (2010) Morphological characteristics of brain tumors causing seizures. Arch Neurol 67(3):336–342. doi:10.​1001/​archneurol.​2010.​2 PubMedCrossRef
19.
Zurück zum Zitat Lakomy R, Fadrus P, Slampa P, Svoboda T, Kren L, Lzicarova E, Belanova R, Sikova I, Poprach A, Schneiderova M, Prochazkova M, Sana J, Slaby O, Smrcka M, Vyzula R, Svoboda M (2011) Multimodal treatment of glioblastoma multiforme: results of 86 consecutive patients diagnosed in period 2003–2009. Klin Onkol 24(2):112–120PubMed Lakomy R, Fadrus P, Slampa P, Svoboda T, Kren L, Lzicarova E, Belanova R, Sikova I, Poprach A, Schneiderova M, Prochazkova M, Sana J, Slaby O, Smrcka M, Vyzula R, Svoboda M (2011) Multimodal treatment of glioblastoma multiforme: results of 86 consecutive patients diagnosed in period 2003–2009. Klin Onkol 24(2):112–120PubMed
21.
Zurück zum Zitat Quan D, Hackney DB, Pruitt AA, Lenkinski RE, Cecil KM (1999) Transient MRI enhancement in a patient with seizures and previously resected glioma: use of MRS. Neurology 53(1):211–213PubMedCrossRef Quan D, Hackney DB, Pruitt AA, Lenkinski RE, Cecil KM (1999) Transient MRI enhancement in a patient with seizures and previously resected glioma: use of MRS. Neurology 53(1):211–213PubMedCrossRef
24.
Zurück zum Zitat Brandes AA, Tosoni A, Spagnolli F, Frezza G, Leonardi M, Calbucci F, Franceschi E (2008) Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology. Neuro Oncol 10(3):361–367. doi:10.1215/15228517-2008-008 PubMedCrossRef Brandes AA, Tosoni A, Spagnolli F, Frezza G, Leonardi M, Calbucci F, Franceschi E (2008) Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology. Neuro Oncol 10(3):361–367. doi:10.​1215/​15228517-2008-008 PubMedCrossRef
Metadaten
Titel
Seizures during the management of high-grade gliomas: clinical relevance to disease progression
verfasst von
Young-Hoon Kim
Chul-Kee Park
Tae Min Kim
Seung Hong Choi
Yu Jung Kim
Byung Se Choi
Jung Ho Han
Se-Hoon Lee
Chae-Yong Kim
In Ah Kim
Dae Seog Heo
Il Han Kim
Dong Gyu Kim
Hee-Won Jung
Publikationsdatum
01.05.2013
Verlag
Springer US
Erschienen in
Journal of Neuro-Oncology / Ausgabe 1/2013
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-013-1094-6

Weitere Artikel der Ausgabe 1/2013

Journal of Neuro-Oncology 1/2013 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.